First and foremost, the lung cancer market is a massive one. Current projections suggest that the company will be worth more than $36 billion annually by the year 2026. So, showing signs of efficacy in this space is a big win.
However, the excitement goes further.
In the clinical study, GNPX was assessing the main ingredient in its oncoprex drug in combination with checkpoint inhibitors and chemotherapy, the two standards of care. The data showed that when combined with TUSC2, these treatments become more effective among some of the most difficult-to-treat metastatic lung cancers.
Should data continue to be positive and this treatment make it to market, it could quickly become a blockbuster.
With a market cap of around $12 million, an opportunity to get in on a market this large, and make a splash on its way in is a welcomed bit of news for GNPX investors.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story!
Join our free mailing list below to receive real-time news alerts!